1. Introduction {#sec1-marinedrugs-15-00202}
===============

Soft corals classified in the genus *Sarcophyton* are the predominant species in many coral reefs. They are endowed with diverse secondary metabolites, including cembranoids \[[@B1-marinedrugs-15-00202],[@B2-marinedrugs-15-00202]\], biscembranoids \[[@B3-marinedrugs-15-00202]\] and steroids \[[@B4-marinedrugs-15-00202]\]. For pharmacological research, some of the metabolites are reported to possess cytotoxic \[[@B5-marinedrugs-15-00202],[@B6-marinedrugs-15-00202]\], antimicrobial \[[@B7-marinedrugs-15-00202]\], and neuroprotective \[[@B8-marinedrugs-15-00202]\] activities. Ecologically, sarcophytoxide, usually found in sarocophyton species, is an allelopathic chemical used in competition for space with scleractinian corals \[[@B9-marinedrugs-15-00202]\]; while another well-known metabolite, sarcophine, is known to have a toxic effect on fishes \[[@B10-marinedrugs-15-00202]\]. In our previous work, we had isolated novel biscembranoids with cytotoxic activity and anti-inflammatory properties from the cultured soft coral *S. glaucum* \[[@B3-marinedrugs-15-00202]\]. Our present investigation disclosed the purification and structural elucidation of five new and ten known isoprenoid-derived compounds from the same wild-type species, collected off the coastline of Taitung County. The structure of **7** was also revised. Cytotoxic activity of the isolates was assayed by the inhibition of cancer cell proliferation.

2. Results and Discussion {#sec2-marinedrugs-15-00202}
=========================

The EtOAc extract of *Sarcophyton glaucum* was repeatedly separated by column chromatography and HPLC to obtain five new isoprenoids **1**‒**5** and ten known compounds **6**‒**15** ([Figure 1](#marinedrugs-15-00202-f001){ref-type="fig"}). By comparing with data in the literature, the known compounds were identified as sarcophine (**6**) \[[@B11-marinedrugs-15-00202]\], lobocrasol (**7**) \[[@B12-marinedrugs-15-00202]\], 3,4-dihydro-4α-hydroxy-Δ^2^-sarcophine (**8**) \[[@B11-marinedrugs-15-00202],[@B13-marinedrugs-15-00202]\], 3,4-dihydro-4β-hydroxy-Δ^2^-sarcophine (**9**) \[[@B11-marinedrugs-15-00202],[@B13-marinedrugs-15-00202]\], crassumol A (**10**) \[[@B14-marinedrugs-15-00202]\], klyflaccicembranol F (**11**) \[[@B15-marinedrugs-15-00202]\], sarcomilasterol (**12**) \[[@B16-marinedrugs-15-00202]\], sarcoaldesterol B (**13**) \[[@B17-marinedrugs-15-00202]\], sarglaucsterol (**14**) \[[@B18-marinedrugs-15-00202]\], loliolide (**15**) \[[@B19-marinedrugs-15-00202]\].

The molecular formula of 3,4,8,16-tetra-*epi*-lobocrasol (**1**), a colorless oil, was determined as C~20~H~30~O~4~ based on the \[M + Na\]^+^ ion peak obtained by (+)-HRESIMS. The ^13^C NMR data showed 20 carbon signals, including evidence of an α,β-unsaturated enone (*δ*~C~ 204.3, 167.0, and 142.8), an additional double bond (*δ*~C~ 133.3 and 128.4), and four oxygenated carbons (*δ*~C~ 83.8, 83.2, 75.9, and 73.6) ([Table 1](#marinedrugs-15-00202-t001){ref-type="table"}). The ^1^H NMR, in conjunction with the HSQC spectra, revealed that the structure of **1** possessed four methyl groups \[*δ*~H~ 2.08 (3H, s), 1.69 (3H, s), 1.35 (3H, s), 1.03 (3H, s)\], an olefinic methine \[*δ*~H~ 5.15 (1H, t, *J* = 7.6 Hz)\], and two oxygenated methines \[*δ*~H~ 4.90 (1H, s); 3.80 (1H, dd, *J* = 9.2, 5.6 Hz)\] ([Table 2](#marinedrugs-15-00202-t002){ref-type="table"}). The above spectral data were similar to those of lobocrasol (**7**) \[[@B12-marinedrugs-15-00202]\], suggesting that **1** might be an epimer of **7**.

Analysis of COSY spectra established four proton spin systems: H-3/H-16, H~2~-5/H~2~-6/H-7, H~2~-9/H~2~-10/H-11, and H~2~-13/H~2~-14 ([Figure 2](#marinedrugs-15-00202-f002){ref-type="fig"}). The HMBC correlations from H~3~-18 to C-3, C-4, and C-5 made the connection of the tetrahydrofuran ring and the 4-hydroxy-3-methylcyclopent-2-enone moiety. The HMBC correlations from H~3~-19 to C-7, C-8, and C-9; from H~3~-20 to C-11, C-12, and C-13; and from H~3~-17 to C-1, C-15, and C-16 combined with correlations from H~2~-14 to C-1, C-2, and C-15 constructed the remaining fragments. Consequently, the planar structures of **1** and **7** were found to be the same. The relative configurations of all the chiral centers in **1** were deduced by interpretation of nuclear Overhauser effect (NOE) data, analysis of ^3^*J*~H-H~ values, and comparison of carbon chemical shifts. As depicted in [Figure 3](#marinedrugs-15-00202-f003){ref-type="fig"}, the NOE cross-peaks of H~3~-18/H-7 supported that they oriented on the same face, and casually assigned these protons to be α-oriented. The downfield-shifted proton H-5a (*δ*~H~ 3.04), deshielded by the C-2 carbonyl group, showed an NOE correlation with H-9b (*δ*~H~ 1.25), while H~3~-19 showed correlations with both H-7 and H-9a (*δ*~H~ 1.50), suggesting that H-7 and C-9 were located in anti-orientation, thus suggesting a β-orientation for H~3~-19. The strong NOE cross-peaks of H~3~-18/H-16 suggested the α-orientation of H-16. A weak NOE correlation was observed between H-16 and H-3, while H-3 also showed a correlation with H~3~-18, and suggested H-3 should be located anti to H-16. This was confirmed by comparing the small ^3^*J*~H-H~ values with those of cyclopent-2-enone analogues, in which adjacent protons with a *trans* configuration showed small coupling constants \[[@B20-marinedrugs-15-00202],[@B21-marinedrugs-15-00202]\]. The *E* geometry for Δ^11^ double bond was deduced by NOE cross-peaks of H-11/H-13b (*δ*~H~ 1.84), as well as by comparing carbon chemical shift for the C-20 at *δ*~C~ 15.3 (\<20 ppm) \[[@B22-marinedrugs-15-00202]\]. Thus, the chemical shift for C-20 of **7** (*δ*~C~ 14.8) revealed the Δ^11^ double bond should possess the *E*, not *Z* geometry, as assigned in the literature \[[@B12-marinedrugs-15-00202]\]. This was further confirmed by our observation of NOE correlation between H-11 and H-13 (*δ*~H~ 2.48) ([Supplementary Materials, Figure S6-3](#app1-marinedrugs-15-00202){ref-type="app"}). The absolute configuration at C-16 of **7** was determined by Lin et al. using Mosher's method \[[@B12-marinedrugs-15-00202]\]. The electronic circular dichroism (ECD) spectrum of **1** showed Cotton effects with approximately opposite signs compared to that of **7** ([Figure 4](#marinedrugs-15-00202-f004){ref-type="fig"}a), suggesting different configurations at C-3 and C-16 for both **1** and **7**. Thus, the absolute configuration of **1** was determined as shown in [Figure 1](#marinedrugs-15-00202-f001){ref-type="fig"}.

The 1,15β-Epoxy-deoxysarcophine (**2**) was isolated as a colorless oil and had a molecular formula of C~20~H~30~O~3~, determined by HRESIMS analysis. The NMR spectra were quite similar to those of 1,15β-epoxy-2-*epi*-deoxysarcophine \[[@B23-marinedrugs-15-00202]\] with the exception of the signals around the tetrahydrofuran (THF) ring. The ^1^H--^1^H COSY and HMBC correlations, as depicted in [Figure 2](#marinedrugs-15-00202-f002){ref-type="fig"}, confirmed that **2** and 1,15β-epoxy-2-*epi*-deoxysarcophine shared the same planar structure. The 14-membered ring of **2** is suggested to be identical to that of sarcophine (**6**), of which the C-7 to C-11 fragment adopted a half-chair conformation \[[@B24-marinedrugs-15-00202]\], due to the fact that both compounds possessed similar key NOE correlation data: H-3/H-7 and H-7/H-11 ([Figure 5](#marinedrugs-15-00202-f005){ref-type="fig"}). The NOE cross-peaks of H-3/H~2~-14, H~2~-14/H~3~-17, as well as H-2/H~3~-18, implied that both the 1,15-epoxy group and H-2 were β-oriented.

The molecular formula of 3,4-dihydro-4α,7β,8α-trihydroxy-Δ^2^-sarcophine (**3**), C~20~H~30~O~5~, was established by HRESIMS, exceeding that of **8** or **9** by 18 mass units. A series of characteristic absorption bands due to hydroxy (3444 cm^−1^) and carbonyl (1747 cm^−1^) groups were assigned from the IR spectrum of **3**. The NMR data of **3** resembled those of **8** and **9**, with significant differences in carbon chemical shifts at C-7 (*δ*~C~ 74.6) and C-8 (*δ*~C~ 74.9), suggesting that **3** is a 7,8-dihydroxy analogue of **8** or **9**. The Δ^2^ and Δ^11^ double bonds were both determined as *E* geometry according to NOE cross-peaks of H-3/H~2~-14 and H-10/H~3~-20, respectively ([Figure 5](#marinedrugs-15-00202-f005){ref-type="fig"}). Moreover, the correlations of H-7/H~3~-19, H-7/H~3~-20, and H-3/H~3~-20 disclosed that these protons located on the same face and subjectively designated as α protons. The above correlations, as well as that of H-6a/H-11, restricted the envenlop conformation for the C-7 to C-11 segment ([Figure 5](#marinedrugs-15-00202-f005){ref-type="fig"}). Accordingly, H~3~-18 was correlated with H-3, but not with H-7, suggesting that this methyl group is likely β-oriented.

*ent*-Sarcophyolide E (**4**), a colorless oil, was found to have a molecular formula of C~20~H~30~O~5~, based on its HRESIMS. Its NMR spectroscopic data ([Table 1](#marinedrugs-15-00202-t001){ref-type="table"} and [Table 2](#marinedrugs-15-00202-t002){ref-type="table"}) were superimposed to that of sarcophyolide E \[[@B11-marinedrugs-15-00202]\]. The ECD spectra of **4** showed a negative Cotton effect for n→π\* (254 nm) and positive π→π\* (230 nm) transitions, which are quite the same as those of the co-isolated sarcophine (**6**) ([Figure 4](#marinedrugs-15-00202-f004){ref-type="fig"}b), but are in opposite signs to those reported for sarcophyolide E \[[@B11-marinedrugs-15-00202]\]. Accordingly, **4** was elucidated as an enantiomer of sarcophyolide E. Surprisingly, the specific optical rotation of sarcophyolide E was reported as \[α\]~[D]{.smallcaps}~ +4, that has the same positive sign as the specific optical rotation value of **4** (\[α\]~[D]{.smallcaps}~ +14). The \[α\]~[D]{.smallcaps}~ of **4** was repeatedly measured and the positive sign was always obtained. The reason for this discrepancy with literature might need to be studied further.

The HRESIMS of 16-deacetyl-halicrasterol B (**5**) showed a sodiated adduct ion peak at *m*/*z* 501.3552, implying a molecular formula of C~29~H~50~O~5~. Its ^1^H NMR spectrum disclosed three methyl singlets (one assignable to be olefinic methyl), four methyl doublets, four oxygenated-methine protons \[4.00 (m, H-3); 3.47 (br s, H-6); 3.88 (td, J = 10.4, 5.2 Hz); 4.62 (d, J = 5.2 Hz, H-16)\], as well as a complex array of aliphatic methine and methylene protons ([Table 3](#marinedrugs-15-00202-t003){ref-type="table"}). The ^13^C NMR spectrum showed a tetra-substituted double bond at *δ*~C~ 148.2 (C-17) and 134.2 (C-20) and five oxygenated carbons at *δ*~C~ 68.2 (C-3), 77.4 (C-5), 76.6 (C-6), 69.6 (C-11), and 73.0 (C-16). The above spectroscopic data were very similar to those of a Δ^17(20)^ sterol, halicrasterol B, with the acetyl signals disappeared in **5**, suggesting that **5** is a deacetyl derivative of halicrasterol B. This was secured by analyzing the ^1^H--^1^H COSY correlations and the HMBC experiments ([Figure 2](#marinedrugs-15-00202-f002){ref-type="fig"}). Compound **5** and halicrasterol B were found to share the same configurations at the side chain segment based on their identical ^13^C NMR data. Accordingly, the structure of **5** was characterized as depicted in [Figure 1](#marinedrugs-15-00202-f001){ref-type="fig"}.

The cytotoxicity of the isolates **1**--**15** against HepG2 (human hepatocellular liver carcinoma), MDA-MB-231 (human breast adenocarcinoma), and A-549 (human lung epithelial cells) cancer cells were assayed. Furthermore, compounds **6**, **8**, **9**, and **12** were also assayed for cytotoxicity against MOLT-4 (human acute lymphoblastic leukemia), SUP-T1 (human T-cell lymphoblastic lymphoma), and U-937 (human histiocytic lymphoma) cell lines. The results showed that compound **12** exhibited cytotoxicity effect against MDA-MB-231, MOLT-4, SUP-T, and U-937 cell lines with IC~50~ values of 13.8, 6.7, 10.5, and 17.7 μg/mL, respectively, while compound **13** was found to possess cytotoxicity against HepG2, MDA-MB-231, and A-549 cell lines with IC~50~ values of 9.7, 14.0, and 15.8 μg/mL. The remaining compounds were found to be not cytotoxic against the above cancer cell lines, with IC~50~ values higher than 20 μg/mL.

3. Experimental Section {#sec3-marinedrugs-15-00202}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-15-00202}
------------------------------------

The optical rotation values and IR spectra were recorded on a JASCO P-1020 digital polarimeter (JASCO Corporation, Tokyo, Japan) and JASCO J-815 spectrophotometer (JASCO Corporation), respectively. A Varian 400 NMR instrument was used to record the ^1^H NMR and ^13^C NMR spectra with the chemical shifts shown as ppm referenced to the solvent residue of CDCl~3~ (*δ*~H~ 7.26 ppm and *δ*~C~ 77.0 ppm), DMSO-*d*~6~ (*δ*~H~ 2.50 ppm and *δ*~C~ 39.5 ppm), and CD~3~OD (*δ*~H~ 3.31 ppm and *δ*~C~ 49.0 ppm). A Bruker APEX II mass spectrometer equipped with an ESI ionization source (Bruker, Bremen, Germany) was used for acquiring high-resolution mass data. The HPLC system was composed of a Shimadzu LC-10AT*~VP~* series pump, a UV detector (Shimadzu, Milan, Italy), and an ODS column (5 µm, 250 × 10 mm, Inertsil ODS-3, GL Science Inc., Tokyo, Japan).

3.2. Animal Material {#sec3dot2-marinedrugs-15-00202}
--------------------

The collection of *S. glaucum* was performed off the coast of Jihui Fishing Port, Taitung county, Taiwan, in March 2013. A −20 °C freezer was used for specimen storage until extraction. Prof. Chang-Feng Dai performed the species identification, and a voucher specimen (JiH-201304) of this soft coral has been deposited in National Sun Yat-sen University.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-15-00202}
-----------------------------

The lyophilized samples of *S. glaucum* (195 g) were chopped and soaked (4 × 24 h) with EtOAc (4 × 2 L). After the solvent was evaporated, a residue (17.35 g) was obtained. The residue of the EtOAc layer was chromatographed by a silica gel column, using a stepwise gradient system composed of EtOAc/*n*-hexane (0:100 to 100:0, each four column volumes) and acetone/EtOAc (0:100 to 100:0, each four column volumes), and eventually washed by MeOH to afford 25 fractions according to TLC analysis. Fraction 19 was subjected to repeated column chromatography (CC) by Sephadex LH-20 (isocratic, acetone), C18 gel (MeOH-H~2~O, 75%), and silica gel (acetone-*n*-hexane, 10%) to obtain subfractions (SFr.) 19-1 and 19-2. In turn, SFr.19-1 was subjected to semipreparative HPLC (MeOH-H~2~O, 73%) to give compound **6** (23.4 mg), while compound **2** (1.3 mg) was obtained from SFr.19-2 using a CH~3~CN-H~2~O (53%) solvent system. Fraction 20 was subjected to an open column chromatography using Sephadex LH-20 (isocratic, acetone) and subsequently purified by C18 column chromatography (MeOH-H~2~O, 90%) to yield two subfractions (SFr. 20-1 and 20-2). Compounds **11** (2.7 mg) and **10** (2.0 mg) were purified from SFr. 20-1 using HPLC (MeOH-H~2~O, 79%). SFr.20-2 was fractionated into two subfractions (SFr. 20-2-1 and SFr. 20-2-2) using C18 CC (MeOH-H~2~O, 64%). Compounds **8** (1.7 mg) and **9** (6.9 mg) were yielded from SFr. 20-2-1 using HPLC (MeOH-H~2~O, 65%), and compounds **3** (2.7 mg) and **15** (2.1 mg) were obtained from SFr. 20-2-2 using eluent of CH~3~CN-H~2~O (33%). Four subfractions (SFr. 22-1--SFr.22-4) were obtained from fraction 22 by C18 CC (MeOH-H~2~O, 80%). Compounds **4** (4.9 mg) and **7** (4.7 mg) were purified from SFr.22-1 using HPLC (MeOH-H~2~O, 64%). Compounds **1** (2.2 mg), **12** (33.6 mg), and **13** (4.8 mg) were isolated from SFr. 22-2, SFr. 22-3, and SFr.22-4, respectively, using HPLC (MeOH-H~2~O: 71% for SFr. 22-2, 79% for SFr. 22-3, and 85% for SFr. 22-4). Fraction 23 was subjected to CC using a C18 column (MeOH-H~2~O, 80%) and subsequently by HPLC (MeOH-H~2~O, 66%) to give compounds **14** (3.6 mg) and **5** (1.4 mg).

3,4,8,16-Tetra-*epi*-lobocrasol (**1**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ --98 (*c* 1.00, CHCl~3~); ECD (MeOH) *λ*~max~ (Δε) 211 (−0.62), 233 (+1.79), 324 (−0.62); IR (KBr) ν~max~ 3419, 2925, 2855, 1698, 1651, 1455, 1380, 1332, 1246, 1080, and 1049 cm^−1^; ^13^C and ^1^H NMR data, see [Table 1](#marinedrugs-15-00202-t001){ref-type="table"} and [Table 2](#marinedrugs-15-00202-t002){ref-type="table"}; ESIMS *m/z* 357 \[M + Na\]^+^; HRESIMS *m/z* 357.2034 \[M + Na\]^+^ (calculated (calcd.) for C~20~H~30~O~4~Na, 357.2036).

1,15β-Epoxy-deoxysarcophine (**2**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −154 (*c* 0.63, CHCl~3~); IR (KBr) ν~max~ 2926, 2855, 1653, 1514, 1455, 1381, 1239, 1164, and 1039 cm^−1^; ^13^C and ^1^H NMR data, see [Table 1](#marinedrugs-15-00202-t001){ref-type="table"} and [Table 2](#marinedrugs-15-00202-t002){ref-type="table"}; ESIMS *m/z* 341 \[M + Na\]^+^; HRESIMS *m/z* 341.2085 \[M + Na\]^+^ (calcd. for C~20~H~30~O~3~Na, 341.2087).

3,4-Dihydro-4α,7β,8α-trihydroxy-Δ^2^-sarcophine (**3**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −84 (*c* 1.28, CHCl~3~); IR (KBr) ν~max~ 3444, 2965, 2929, 2857, 1747, 1668, 1638, 1455, 1373, 1317, 1260, 1127, 1062, and 1018 cm^−1^; ^13^C and ^1^H NMR data, see [Table 1](#marinedrugs-15-00202-t001){ref-type="table"} and [Table 2](#marinedrugs-15-00202-t002){ref-type="table"}; ESIMS *m/z* 373 \[M + Na\]^+^; HRESIMS *m/z* 373.1986 \[M + Na\]^+^ (calcd. for C~20~H~30~O~5~Na, 373.1986).

*ent*-Sarcophyolide E (**4**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ +14 (*c* 1.70, CHCl~3~); ECD (MeOH) *λ*~max~ (Δε) 230 (+1.41), 254 (−0.40); ^13^C and ^1^H NMR data, see [Table 1](#marinedrugs-15-00202-t001){ref-type="table"} and [Table 2](#marinedrugs-15-00202-t002){ref-type="table"}; ESIMS *m/z* 373 \[M + Na\]^+^; HRESIMS *m/z* 373.1984 \[M + Na\]^+^ (calcd. for C~20~H~30~O~5~Na, 373.1986).

16-Deacetyl-halicrasterol B (**5**): white powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −111 (*c* 0.78, CHCl~3~); IR (KBr) ν~max~ 3330, 2922, 2854,1652, 1598, 1455, 1374, and 1023 cm^−1^; ^13^C and ^1^H NMR data, see [Table 3](#marinedrugs-15-00202-t003){ref-type="table"}; ESIMS *m/z* 501 \[M + Na\]^+^; HRESIMS *m/z* 501.3552 \[M + Na\]^+^ (calcd. for C~29~H~50~O~5~Na, 501.3551).

Sarcophine (**6**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ +139 (*c* 4.98, CHCl~3~); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ +97 (*c* 0.01, CHCl~3~); ECD (MeOH) *λ*~max~ (Δε) 229 (+1.22), 248 (−1.58); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B11-marinedrugs-15-00202]\].

Lobocrasol (**7**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −212 (*c* 0.05, CHCl~3~); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −186 (*c* 0.10, CHCl~3~); ECD (MeOH) *λ*~max~ (Δε) 215 (+0.57), 240 (−1.66), 325 (+0.81); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B12-marinedrugs-15-00202]\].

3,4-Dihydro-4α-hydroxy-Δ^2^-sarcophine (**8**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −17 (*c* 0.50, CHCl~3~); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −5 (*c* 0.10, CHCl~3~); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B11-marinedrugs-15-00202],[@B13-marinedrugs-15-00202]\].

3,4-Dihydro-4β-hydroxy-Δ^2^-sarcophine (**9**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −1 (*c* 1.53, CHCl~3~); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −1 (*c* 0.10, CHCl~3~); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B11-marinedrugs-15-00202],[@B13-marinedrugs-15-00202]\].

Srassumol A (**10**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −30 (*c* 0.49, CHCl~3~); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −20 (*c* 0.10, CHCl~3~); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B14-marinedrugs-15-00202]\].

Klyflaccicembranol F (**11**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −76 (*c* 1.28, CHCl~3~); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −32 (*c* 0.60, CHCl~3~); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B15-marinedrugs-15-00202]\].

Sarcomilasterol (**12**): amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ +30 (*c* 0.67, CHCl~3~); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{20}$ +5 (*c* 0.08, CHCl~3~); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B16-marinedrugs-15-00202]\].

Sarcoaldesterol B (**13**): amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −21 (*c* 1.50, MeOH); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −20 (*c* 0.23, MeOH); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B17-marinedrugs-15-00202]\].

Sarglaucsterol (**14**): amorphous solid; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −15 (*c* 0.45, MeOH); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{20}$ −25 (*c* 0.11, MeOH); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B18-marinedrugs-15-00202]\].

Loliolide (**15**): colorless oil; $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}^{25}$ −11 (*c* 0.73, CHCl~3~); lit. $\left\lbrack \mathsf{\alpha} \right\rbrack_{\ D}$ −92 (*c* 1.10, CHCl~3~); MS, ^1^H and ^13^C NMR data were found to be in full agreement with literature data \[[@B19-marinedrugs-15-00202]\].

3.4. Cytotoxicity Assay {#sec3dot4-marinedrugs-15-00202}
-----------------------

HepG2, MDA-MB-231, A-549, MOLT-4, SUP-T1, and U-937 cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). The MTT assays were performed as previous reported \[[@B25-marinedrugs-15-00202]\]. After a 15 h culture for the above cancer cell lines, the isolated compounds prepared in different concentrations of DMSO were added for an additional 72 h culture \[[@B25-marinedrugs-15-00202]\]. The cytotoxic potential of the isolated compounds was evaluated by means of a MTT \[3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide\] cell proliferation assay and the absorbance was measured using an ELISA reader and monitored at 570 and 620 nm, which allowed the calculation of IC~50~ values.

4. Conclusions {#sec4-marinedrugs-15-00202}
==============

Our present study discovered four new diterpenoids **1**--**4** and a new steroid 5 as well as ten known compounds **6--15**. The 3,4,8,16-tetra-*epi*-lobocrasol (**1**) represent the second example of lobocrasol-type diterpenoid, while the Δ^11^ double in lobocrasol (**7**) was revised as *E* geometry in this study. It is interesting that, similar to sarcophine and *ent*-sarcophine \[[@B26-marinedrugs-15-00202]\], sarcophyolide E and *ent*-sarcophyolide E (**4**) were also isolated from the same genus.
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The ^1^H and ^13^C NMR spectra of compounds **1**--**5** and **7** (Figures S1--S6), and partial NOESY spectrum of **7** (Figure S6-3) are available online at <http://www.mdpi.com/1660-3397/15/7/202/s1>.
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marinedrugs-15-00202-t001_Table 1

###### 

^13^C NMR spectroscopic data of compounds **1**‒**3** (100 MHz, CDCl~3~) and **4** (100 MHz, DMSO-*d*~6~).

  No.   1              2              3              4
  ----- -------------- -------------- -------------- --------------
  1     142.8 (C)      71.9 (C)       152.2 (C)      165.3 (C)
  2     204.3 (C)      76.6 (CH)      148.2 (C)      79.6 (CH)
  3     59.4 (CH)      122.4 (CH)     116.5 (CH)     119.5 (CH)
  4     83.2 (C)       140.0 (C)      74.2 (C)       143.8 (C)
  5     32.4 (CH~2~)   37.9 (CH~2~)   38.8 (CH~2~)   35.7 (CH~2~)
  6     25.0 (CH~2~)   25.4 (CH~2~)   26.9 (CH~2~)   24.2 (CH~2~)
  7     83.8 (CH)      61.9 (CH)      74.6 (CH)      83.4 (CH)
  8     73.6 (C)       59.8 (C)       74.9 (C)       68.3 (C)
  9     34.0 (CH~2~)   40.2 (CH~2~)   38.0 (CH~2~)   40.3 (CH~2~)
  10    21.5 (CH~2~)   23.7 (CH~2~)   22.1 (CH~2~)   23.0 (CH~2~)
  11    128.4 (CH)     123.9 (CH)     128.5 (CH)     80.0 (CH)
  12    133.3 (C)      136.1 (C)      131.4 (C)      71.3 (C)
  13    39.1 (CH~2~)   35.2 (CH~2~)   38.3 (CH~2~)   36.8 (CH~2~)
  14    20.0 (CH~2~)   27.5 (CH~2~)   22.3 (CH~2~)   20.1 (CH~2~)
  15    167.0 (C)      67.4 (C)       123.7 (C)      121.2 (C)
  16    75.9 (CH)      69.4 (CH~2~)   170.3 (C)      174.5 (C)
  17    13.2 (CH~3~)   12.1 (CH~3~)   8.8 (CH~3~)    8.5 (CH~3~)
  18    25.2 (CH~3~)   15.6 (CH~3~)   29.5 (CH~3~)   16.2 (CH~3~)
  19    25.8 (CH~3~)   16.7 (CH~3~)   25.5 (CH~3~)   20.0 (CH~3~)
  20    15.3 (CH~3~)   14.9 (CH~3~)   15.9 (CH~3~)   23.4 (CH~3~)

marinedrugs-15-00202-t002_Table 2

###### 

^1^H NMR spectroscopic data of compounds **1**‒**3** (400 MHz, CDCl~3~) and **4** (400 MHz, DMSO-*d*~6~).

  No.   1                     2                     3                    4
  ----- --------------------- --------------------- -------------------- ---------------------
  2     \-                    4.87 d (11.2)         \-                   5.53 d (10.4)
  3     2.16 br s             5.26 dd (10.8, 0.8)   5.21 s               4.99 d (10.4)
  5     3.04 q (10.8)         2.34 m                2.09 m               2.18 m
        1.67 m                \-                    1.78 m               \-
  6     2.00 dd (9.6, 2.4)    1.92 m                1.54 m               1.97 m
        1.54 m                1.63 m                1.51 m               1.42 m
  7     3.80 dd (9.2, 5.6)    2.65 t (4.0)          3.52 dd (9.2, 3.2)   3.01 dd (10.0, 2.8)
  9     1.50 m                2.13 m                1.64 m               1.73 m
        1.25 m                0.93 m                1.47 m               1.49 m
  10    2.05 m                2.27 m                2.17 m               1.62 m
        1.90 m                1.87 m                1.86 m               1.34 m
  11    5.15 t (7.6)          5.11 dd (9.6, 5.6)    4.99 t (6.8)         3.13 d (10.4)
  13    2.28 br d (13.2)      2.22 m                2.28 m               1.70 m
        1.84 m                1.95 m                \-                   1.49 m
  14    2.61 td (13.2, 2.1)   1.69 m                2.56 m               2.45 m
        2.12 m                \-                    \-                   1.91 m
  16    4.90 br s             3.89 d (10.4)         \-                   \-
        \-                    3.75 d (10.4)         \-                   \-
  17    2.08 s                1.43 s                1.94 s               1.73 s
  18    1.35 s                1.84 s                1.40 s               1.77 s
  19    1.03 s                1.27 s                1.61 s               0.98 s
  20    1.69 s                1.57 s                1.67 s               0.98 s

marinedrugs-15-00202-t003_Table 3

###### 

^1^H and ^13^C NMR spectroscopic data of compound **5**.

  No.   *δ*~H~ (*J* in Hz) ^a^   *δ*~C~ (mult.) ^b^   No.   *δ*~H~ (*J* in Hz) ^a^   *δ*~C~ (mult.) ^b^
  ----- ------------------------ -------------------- ----- ------------------------ --------------------
  1     1.99 m                   35.2 (CH~2~)         15    1.62 m                   36.5 (CH~2~)
        1.54 m                   \-                   \-    1.45 m                   \-
  2     1.75 m                   32.0 (CH~2~)         16    4.62 d (5.2)             73.0 (CH)
        1.51 m                   \-                   17    \-                       148.2 (C)
  3     4.00 m                   68.2 (CH)            18    0.91 s                   18.8 (CH~3~)
  4     2.09 dd (13.2, 11.6)     42.0 (CH~2~)         19    1.28 s                   17.5 (CH~3~)
        1.54 m                   \-                   20    \-                       134.2 (C)
  5     \-                       77.4 (C)             21    1.77 s                   17.5 (CH~3~)
  6     3.47 br s                76.6 (CH)            22    2.41 dd (13.2, 10.8)     43.0 (CH~2~)
  7     1.84 m                   35.3 (CH~2~)         \-    1.91 m                   \-
  8     1.88 m                   29.1 (CH)            23    1.86 m                   34.0 (CH)
  9     1.57 m                   53.3 (CH)            24    1.09 m                   45.9 (CH)
  10    \-                       41.1 (C)             25    1.64 m                   31.3 (CH)
  11    3.88 td (10.4, 5.2)      69.6 (CH)            26    0.87 d (6.8)             19.6 (CH~3~)
  12    2.62 dd (12.0, 5.2)      50.2 (CH~2~)         27    0.93 d (6.8)             22.0 (CH~3~)
        1.58 m                   \-                   28    0.82 d (6.8)             11.9 (CH~3~)
  13    \-                       46.0 (C)             29    0.72 d (6.8)             13.9 (CH~3~)
  14    1.78 m                   52.5 (CH)            \-    \-                       \-

^a^ Spectra recorded at 400 MHz in CD~3~OD; ^b^ spectra recorded at 100 MHz in CD~3~OD.

[^1]: These authors contributed equally to this work.
